Byonanebye, Dathan M., Polizzotto, Mark N., Begovac, Josip, Grabmeier-Pfistershammer, Katharina, Abela, Irene, Castagna, Antonella, De Wit, Stephane, Mussini, Cristina ORCID: 0000-0002-6615-4198, Vehreschild, Joerg J., Monforte, Antonella d'A, Wit, Ferdinand W. N. M., Pradier, Christian, Chkhartishvili, Nikoloz, Sonnerborg, Anders, Hoy, Jennifer, Lundgren, Jens, Neesgaard, Bastian, Bansi-matharu, Loveleen, Greenberg, Lauren, Llibre, Josep M., Vannappagari, Vani, Gallant, Joel, Necsoi, Coca, Cichon, Piotr, Reiss, Peter, Aho, Inka, Tsertsvadze, Tengiz ORCID: 0000-0002-4986-7874, Mennozzi, Marianna, Rauch, Andri ORCID: 0000-0001-5297-6062, Muccini, Camilla ORCID: 0000-0002-0900-5639, Law, Matthew, Mocroft, Amanda, Ryom, Lene and Petoumenos, Kathy (2021). Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. Aids, 35 (6). S. 869 - 883. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1473-5571

Full text not available from this repository.

Abstract

Objective: To compare the incidence of dyslipidemia in people with HIV receiving integrase inhibitors (INSTI) versus boosted protease inhibitors (PI/b) and nonnucleoside reverse transcriptase inhibitors (NNRTI) within RESPOND consortium of prospective cohorts. Methods: Participants were eligible if they were at least 18 years, without dyslipidemia and initiated or switched to a three-drug antiretroviral therapy (ART)-regimen consisting of either INSTI, NNRTI, or PI/b for the first time, between 1 January 2012 and 31 December 2018. Dyslipidemia was defined as random total cholesterol more than 240 mg/dl, HDL less than 35 mg/dl, triglyceride more than 200 mg/dl, or initiation of lipid-lowering therapy. Poisson regression was used to determine the adjusted incidence rate ratios. Follow-up was censored after 3 years or upon ART-regimen discontinuation or last lipid measurement or 31 December 2019, whichever occurred first. Results: Overall, 4577 people with HIV were eligible (INSTI = 66.9%, PI/b = 12.5%, and NNRTI = 20.6%), 1938 (42.3%) of whom were ART-naive. During 1.7 (interquartile range, 0.6-3.0) median years of follow-up, 1460 participants developed dyslipidemia [incidence rate: 191.6 per 1000 person-years, 95% confidence interval (CI) 182.0-201.7]. Participants taking INSTI had a lower incidence of dyslipidemia compared with those on PI/b (adjusted incidence rate ratio 0.71; CI 0.59-0.85), but higher rate compared with those on NNRTI (1.35; CI 1.15-1.58). Compared with dolutegravir, the incidence of dyslipidemia was higher with elvitegravir/cobicistat (1.20; CI 1.00-1.43) and raltegravir (1.24; CI 1.02-1.51), but lower with rilpivirine (0.77; CI 0.63-0.94). Conclusion: In this large consortium of heterogeneous cohorts, dyslipidemia was less common with INSTI than with PI/b. Compared with dolutegravir, dyslipidemia was more common with elvitegravir/cobicistat and raltegravir, but less common with rilpivirine.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Byonanebye, Dathan M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Polizzotto, Mark N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Begovac, JosipUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grabmeier-Pfistershammer, KatharinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Abela, IreneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Castagna, AntonellaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
De Wit, StephaneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mussini, CristinaUNSPECIFIEDorcid.org/0000-0002-6615-4198UNSPECIFIED
Vehreschild, Joerg J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Monforte, Antonella d'AUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wit, Ferdinand W. N. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pradier, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chkhartishvili, NikolozUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sonnerborg, AndersUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hoy, JenniferUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lundgren, JensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Neesgaard, BastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bansi-matharu, LoveleenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Greenberg, LaurenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Llibre, Josep M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vannappagari, VaniUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gallant, JoelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Necsoi, CocaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cichon, PiotrUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reiss, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Aho, InkaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tsertsvadze, TengizUNSPECIFIEDorcid.org/0000-0002-4986-7874UNSPECIFIED
Mennozzi, MariannaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rauch, AndriUNSPECIFIEDorcid.org/0000-0001-5297-6062UNSPECIFIED
Muccini, CamillaUNSPECIFIEDorcid.org/0000-0002-0900-5639UNSPECIFIED
Law, MatthewUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mocroft, AmandaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ryom, LeneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Petoumenos, KathyUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-606826
DOI: 10.1097/QAD.0000000000002811
Journal or Publication Title: Aids
Volume: 35
Number: 6
Page Range: S. 869 - 883
Date: 2021
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Place of Publication: PHILADELPHIA
ISSN: 1473-5571
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CARDIOVASCULAR RISK; TENOFOVIR ALAFENAMIDE; TREATMENT-NAIVE; LIPID PROFILES; MYOCARDIAL-INFARCTION; OBSERVATIONAL COHORT; PROTEASE INHIBITOR; INFECTED PATIENTS; DATA-COLLECTION; SERUM-LIPIDSMultiple languages
Immunology; Infectious Diseases; VirologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60682

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item